Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. (Nasdaq: IFRX) is a biopharmaceutical company that regularly issues news on its clinical programs targeting the complement system, particularly the C5a/C5aR axis. Company updates highlight progress with its oral C5a receptor inhibitor izicopan (also referenced as INF904) and its intravenously delivered anti-C5a monoclonal antibody vilobelimab, including GOHIBIC (vilobelimab) for SARS-CoV-2-induced acute respiratory distress syndrome in the European Union.
News about InflaRx often covers clinical trial milestones, such as Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria for izicopan, as well as analyses of Phase 3 data for vilobelimab in pyoderma gangrenosum. Releases also describe regulatory interactions, including anticipated discussions with the U.S. Food and Drug Administration, and strategic decisions about prioritizing resources toward izicopan and adjusting spending on GOHIBIC (vilobelimab).
Investors following IFRX news can expect announcements on clinical data readouts, participation in healthcare and investor conferences, and business updates related to funding, cash runway and partnering activities. InflaRx’s communications have included information on BARDA-supported studies in acute respiratory distress syndrome, co-development activities for an anti-C5a antibody in China, and notices regarding Nasdaq listing requirements.
This news feed aggregates InflaRx’s press releases and related coverage so readers can review clinical developments, regulatory updates and corporate actions in one place. For those tracking complement-targeted therapeutics, IFRX news provides insight into how the company is advancing its C5a and C5aR inhibitor programs across dermatologic and respiratory indications and how it is aligning its strategy and capital allocation with these priorities.
InflaRx (NASDAQ:IFRX) reported Q2 2025 financial results and provided key updates on its pipeline. The company's cash position stands at €53.7 million, with runway extending into 2027. Key developments include anticipated INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by early November 2025.
Financial highlights show a net loss of €23.0 million (€0.35 per share) for H1 2025. The company's partner Staidson BioPharmaceuticals reported favorable Phase 1/2 results for BDB-001 in ANCA-associated vasculitis, planning to advance to Phase 3. The previously announced Phase 3 pyoderma gangrenosum trial was stopped due to futility, with full data analysis expected later this year.
Additionally, enrollment began in the BARDA-funded JUST BREATHE Phase 2 platform trial investigating vilobelimab for acute respiratory distress syndrome (ARDS). The company maintains EU approval for GOHIBIC (vilobelimab) in SARS-CoV-2-induced ARDS and is pursuing commercial partnerships.
InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has scheduled its second quarter 2025 financial results announcement for August 7, 2025, before market opening. No earnings call is planned.
The company specializes in developing therapeutics targeting the complement system, particularly the C5a inflammatory mediator. Their key developments include vilobelimab, an intravenous anti-C5a monoclonal antibody, and INF904, an oral small molecule C5a receptor inhibitor. InflaRx maintains operations in Jena and Munich, Germany, and Ann Arbor, Michigan, USA.
InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has received a Nasdaq deficiency notice on July 11, 2025, for failing to maintain the minimum bid price requirement of $1.00 per share for the last 30 consecutive business days.
The company has been granted an initial 180-day period until January 7, 2026, to regain compliance. If unsuccessful, InflaRx may consider transferring from Nasdaq Global Select Market to Nasdaq Capital Market, which could provide an additional 180 days until July 6, 2026, subject to meeting other listing requirements.
InflaRx develops anti-C5a and anti-C5a receptor technologies, including vilobelimab, an intravenous antibody, and INF904, an oral small molecule inhibitor.
InflaRx, a pioneering biopharmaceutical company listed on Nasdaq (IFRX), has announced it will release its first quarter 2025 financial and operating results on May 7, 2025, before market opening. No earnings call is scheduled.
The company specializes in developing anti-inflammatory therapeutics by targeting the complement system, specifically the C5a and C5aR pathways. Their flagship product, vilobelimab, is an intravenous first-in-class anti-C5a antibody that has shown promising clinical results across multiple indications. Additionally, they are developing INF904, an oral C5a receptor inhibitor.
Founded in 2007, InflaRx maintains offices in Jena and Munich, Germany, and Ann Arbor, Michigan, USA. The company operates through two wholly owned subsidiaries: InflaRx GmbH in Germany and InflaRx Pharmaceuticals in the USA.
InflaRx (IFRX) reported key achievements for 2024 and milestones for 2025. The company received European Commission approval for GOHIBIC® (vilobelimab) to treat SARS-CoV-2-induced ARDS. They reached a 30-patient recruitment milestone in Phase 3 vilobelimab trial for pyoderma gangrenosum, with interim analysis expected by May 2025.
Financial highlights include:
- Cash position of €55.2 million as of December 31, 2024
- Additional €28.7 million raised through public offering in February 2025
- Cash runway extended into 2027
- Net loss of €46.1 million (€0.78 per share) in 2024
- R&D expenses decreased to €35.4 million
The company dosed first patient in Phase 2a trial for oral C5aR inhibitor INF904, with topline data in chronic spontaneous urticaria and hidradenitis suppurativa expected in summer 2025. Multiple data presentations at AAD 2025 highlighted vilobelimab's potential in reducing systemic inflammation.
InflaRx (NASDAQ: IFRX) presented multiple data sets for vilobelimab at the 2025 AAD Annual Meeting, showcasing its potential in treating inflammatory conditions. The presentations included results from studies in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).
Key findings for PG showed vilobelimab was well-tolerated with mostly mild to moderate adverse events. The PK/PD data demonstrated approximately 90% reduction in C5a levels by Day 15, sustained through Day 99 in higher dose groups.
In HS, the Phase 2b SHINE trial revealed significant improvements:
- 63.2% reduction in draining tunnels versus 18.0% for placebo
- 40.9% complete resolution of draining tunnels versus 13.0% for placebo (3.1x improvement)
- 800mg vilobelimab significantly reduced C5a concentrations from Day 1
- Safety analysis showed the drug was well-tolerated across all doses
InflaRx N.V. (Nasdaq: IFRX) announced that all their submitted abstracts featuring vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) have been accepted for presentation at the 2025 American Academy of Dermatology Annual Meeting in Orlando, FL.
The presentations include first-time data on reduction in draining tunnels with vilobelimab in HS patients, and insights on a modified HiSCR scoring system. The abstracts cover safety studies, pharmacokinetic/pharmacodynamic analyses, and efficacy data from Phase 2 trials in both PG and HS conditions.
Vilobelimab, a first-in-class monoclonal anti-human complement factor C5a antibody, is currently in Phase 3 trials for PG and has received orphan drug designation from both FDA and EMA, plus FDA fast track designation for PG treatment.